A Study to Evaluate the Safety and Tolerability | Clinical Research Studies Listing

A Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies

Recruiting

18 years - 99 years

All

Phase 1

150 participants needed

1 Location

Brief description of study

A study to evaluate the safety, tolerability, PK, pharmacodynamics, and clinical activity of AB680 (CD73 inhibitor) in combination with AB122 (programmed cell death-1 inhibitor) and standard chemotherapy (nab-paclitaxel [NP] and gemcitabine [Gem]) in participants with advanced pancreatic cancer.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: pancreatic cancer
Age: 18 years - 99 years
Gender: All

Male or Female Age 18 or older Diagnosis of pancreatic cancer

Updated on 04 Aug 2024. Study ID: 843630

Find a site

Your Information has been sent successfully.

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.

Would you like to be notified about other trials? Sign up for Patient Notification Services.

Send a message

Enter your contact details to connect with study team

Primary Contact

First name*

Last name*

Email*

Phone number*

Preferred way of contact

Race

Ethnicity

Are you Healthy Volunteer

Are you comfortable with the informed consent process?

Yes

Other language

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants with Gastrointestinal Malignancies

Brief description of study

Eligibility of study

Find a site

Interested in the study